Insurance stocks tend to trade on theReinsurancepricing cycle and on bond yields rather than daily market sentiment, and neither shifted decisively on Friday. The only company filing was an amended Form 8-K signed November 13 by general counsel Shannon Lowry Bender. It amends a …
With the print five sessions away and a broad market that sold off in technology but held up elsewhere, StoneX traded like a stock waiting for its own catalyst. The S&P 500 fell 0.4%, the Nasdaq Composite fell 0.9% and the Russell 2000 slipped …
The International Energy Agency's November Oil Market Report, released on Friday, said the global oil market is swinging back to surplus for the first time since the Iran war began. It added that severe tightness in refined products, especially diesel, remains its overriding concern. …
Ventas issued no company announcement on Friday. The latest analyst move was positive. UBS raised its price target to $99 from $90 on November 11, which implies about 11% upside from Friday's close, and Morgan Stanley reaffirmed a Hold rating on November 10.
Treasury yields rose on Friday, and higher yields tend to pressure real estateInvestmenttrusts because they raise borrowing costs and make dividend-paying stocks less attractive next to bonds. Peers in senior housing and net-lease real estate, including Ventas (NYSE:VTR) and Realty Income (NYSE:O), also finished …
The broader market was weak, with the S&P 500 down 0.4% and the Russell 2000 down 0.3%, so World Kinect's gain was a clear outperformance.
Destination XL Group, Inc. filed a definitive proxy statement on November 16, 2026, soliciting stockholder votes for its 2026 Annual Meeting to be held on December 17, 2026, at the company's Canton, Massachusetts headquarters.
StandardAero, Inc. filed an 8-K on November 16, 2026, disclosing a $600 million incremental term loan facility executed on November 13, 2026, and a $350 million accelerated share repurchase agreement entered into the same day with Morgan Stanley & Co. LLC.
Minerva Neurosciences, Inc. filed a Form 8-K on November 16, 2026, furnishing a revised transcript of a key opinion leader event held on November 12, 2026, related to roluperidone, its product candidate for negative symptoms in schizophrenia patients.
Bruker Corporation filed a Form 8-K on November 16, 2026, disclosing the appointment of Eicke Latz MD PhD to its Board of Directors effective January 1, 2027, and the declaration of a quarterly cash dividend of $0.05 per share on its common stock.